What question did this study set out to answer?

To enhance anti-PD-1 therapy efficacy by targeting the non-canonical immune checkpoint MUC1-C in solid tumors.

Targeting MUC1-C Enhances Anti-PD-1 Therapy in Solid Tumors

View Full Paper

Ask AI

Bookmark

Authors

Demonstrates enhanced tumor growth inhibition in solid tumors through novel dual-checkpoint blockade, implying improved cancer treatment options.

To enhance anti-PD-1 therapy efficacy by targeting the non-canonical immune checkpoint MUC1-C in solid tumors.
Utilized syngeneic tumor model with MC38-hMUC1 colon adenocarcinoma cells expressing human MUC1
Combined anti-PD-1 therapy with PAb001, a humanized IgG1 antibody targeting MUC1-C
Evaluated tumor growth inhibition (TGI) using combinatorial treatment strategy
Achieved tumor growth inhibition of 91.3% with the dual-checkpoint blockade
Observed robust antitumor activity in the treated tumor models
Identified potential for additional anti-MUC1 antibodies to enhance treatment protocols

Kim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Demonstrates enhanced tumor growth inhibition in solid tumors through novel dual-checkpoint blockade, implying improved cancer treatment options.

To enhance anti-PD-1 therapy efficacy by targeting the non-canonical immune checkpoint MUC1-C in solid tumors.
Utilized syngeneic tumor model with MC38-hMUC1 colon adenocarcinoma cells expressing human MUC1
Combined anti-PD-1 therapy with PAb001, a humanized IgG1 antibody targeting MUC1-C
Evaluated tumor growth inhibition (TGI) using combinatorial treatment strategy
Achieved tumor growth inhibition of 91.3% with the dual-checkpoint blockade
Observed robust antitumor activity in the treated tumor models
Identified potential for additional anti-MUC1 antibodies to enhance treatment protocols

Kim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark